{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:14:21Z","timestamp":1793247261464,"version":"4.5.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cabotegravir (CAB) + rilpivirine (RPV) dosed intramuscularly monthly or every 2 months is a complete, long-acting (LA) regimen for the maintenance of HIV-1 virologic suppression. Here, we report the antiretroviral therapy as long acting suppression (ATLAS)-2M study week 152 results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>ATLAS-2M is a phase 3b, randomized, multicenter study assessing the efficacy and safety of CAB+RPV LA every 8 weeks (Q8W) versus every 4 weeks (Q4W). Virologically suppressed (HIV-1 RNA &amp;lt;50 copies\/mL) individuals were randomized to receive CAB+RPV LA Q8W or Q4W. Endpoints included the proportion of participants with plasma HIV-1 RNA \u226550 copies\/mL and &amp;lt;50 copies\/mL, incidence of confirmed virologic failure (CVF; 2 consecutive measurements \u2265200 copies\/mL), safety, and tolerability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 1045 participants received CAB+RPV LA (Q8W, n = 522; Q4W, n = 523). CAB+RPV LA Q8W demonstrated noninferior efficacy versus Q4W dosing, with 2.7% (n = 14) and 1.0% (n = 5) of participants having HIV-1 RNA \u226550 copies\/mL, respectively, with adjusted treatment difference being 1.7% (95% CI: 0.1\u20133.3%), meeting the 4% noninferiority threshold. At week 152, 87% of participants maintained HIV-1 RNA &amp;lt;50 copies\/mL (Q8W, 87% [n = 456]; Q4W, 86% [n = 449]). Overall, 12 (2.3%) participants in the Q8W arm and 2 (0.4%) in the Q4W arm had CVF. Eight and 10 participants with CVF had treatment-emergent, resistance-associated mutations to RPV and integrase inhibitors, respectively. Safety profiles were comparable, with no new safety signals observed since week 48.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These data demonstrate virologic suppression durability with CAB+RPV LA Q8W or Q4W for \u223c3 years and confirm long-term efficacy, safety, and tolerability of CAB+RPV LA as a complete regimen to maintain HIV-1 virologic suppression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciad020","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T01:02:26Z","timestamp":1674003746000},"page":"1646-1654","source":"Crossref","is-referenced-by-count":145,"title":["Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study"],"prefix":"10.1093","volume":"76","author":[{"given":"Edgar T","family":"Overton","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, University of Alabama at Birmingham , Birmingham, Alabama , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Richmond","sequence":"additional","affiliation":[{"name":"Department of Medicine, Broward Health Medical Center , Fort Lauderdale, Florida , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliano","family":"Rizzardini","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Fatebenefratelli Sacco Hospital , Milan , Italy"},{"name":"School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand , Johannesburg , South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Thalme","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Karolinska University Hospital , Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Marie","family":"Girard","sequence":"additional","affiliation":[{"name":"Department of Infectious and Tropical Diseases and Inserm, University of Paris, St-Antoine Hospital , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Saskatchewan , Regina , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norma","family":"Porteiro","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n IDEAA , Buenos Aires , Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Swindells","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Nebraska Medical Center , Omaha, Nebraska , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Reynes","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Montpellier University Hospital , Montpellier , France"},{"name":"Inserm, University of Montpellier , Montpellier , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Noe","sequence":"additional","affiliation":[{"name":"HIV Research and Clinical Care Center, MVZ M\u00fcnchen Am Goetheplatz , Munich , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conn","family":"Harrington","sequence":"additional","affiliation":[{"name":"Clinical Development, ViiV Healthcare , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Mart\u00edn","family":"Espa\u00f1ol","sequence":"additional","affiliation":[{"name":"GSK , Brentford , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Acuipil","sequence":"additional","affiliation":[{"name":"Research and Development, ViiV Healthcare , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma","family":"Aksar","sequence":"additional","affiliation":[{"name":"GSK , Manchester , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Development Biostatistics, GSK , Collegeville, Pennsylvania , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L","family":"Ford","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Modeling and Simulation, GSK , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herta","family":"Crauwels","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Janssen Research and Development , Beerse , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerle","family":"van Eygen","sequence":"additional","affiliation":[{"name":"Clinical Microbiology and Immunology, Janssen Research and Development , Beerse , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodica","family":"Van Solingen-Ristea","sequence":"additional","affiliation":[{"name":"Medical Department, Janssen Research and Development , Beerse , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine L","family":"Latham","sequence":"additional","affiliation":[{"name":"Translational Medicine Research, ViiV Healthcare , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanker","family":"Thiagarajah","sequence":"additional","affiliation":[{"name":"Pharma Safety, GSK , Brentford , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"D\u2019Amico","sequence":"additional","affiliation":[{"name":"Research and Development, ViiV Healthcare , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly Y","family":"Smith","sequence":"additional","affiliation":[{"name":"Research and Development, ViiV Healthcare , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kati","family":"Vandermeulen","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Janssen Research and Development , Beerse , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R","family":"Spreen","sequence":"additional","affiliation":[{"name":"Research and Development, ViiV Healthcare , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,1,20]]},"reference":[{"key":"2023071416150775400_ciad020-B1","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/dyv352","article-title":"The effect of antiretroviral therapy on all-cause mortality, generalized to persons diagnosed with HIV in the USA, 2009-11","volume":"45","author":"Lesko","year":"2016","journal-title":"Int J Epidemiol"},{"key":"2023071416150775400_ciad020-B2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.7326\/0003-4819-135-1-200107030-00005","article-title":"Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease","volume":"135","author":"Murphy","year":"2001","journal-title":"Ann Intern Med"},{"key":"2023071416150775400_ciad020-B3","author":"US Department of Health and Human Services"},{"key":"2023071416150775400_ciad020-B4","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2147\/PPA.S192735","article-title":"Adherence to HIV treatment regimens: systematic literature review and meta-analysis","volume":"13","author":"Altice","year":"2019","journal-title":"Patient Prefer Adherence"},{"issue":"Suppl 2","key":"2023071416150775400_ciad020-B5","doi-asserted-by":"crossref","first-page":"S481","DOI":"10.1093\/ofid\/ofz360.1193","article-title":"1329. Experiences and emotional challenges of antiretroviral treatment (ART)\u2014findings from the positive perspectives study","volume":"6","author":"De Los Rios","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2023071416150775400_ciad020-B6","doi-asserted-by":"crossref","first-page":"e011453","DOI":"10.1136\/bmjopen-2016-011453","article-title":"Examining the associations between HIV-related stigma and health outcomes in people living with HIV\/AIDS: a series of meta-analyses","volume":"6","author":"Rueda","year":"2016","journal-title":"BMJ Open"},{"key":"2023071416150775400_ciad020-B7","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1080\/09540121.2020.1764906","article-title":"Acceptability and preferences for long-acting antiretroviral formulations among people with HIV infection","volume":"33","author":"Dandachi","year":"2021","journal-title":"AIDS Care"},{"key":"2023071416150775400_ciad020-B8","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1136\/sextrans-2020-054648","article-title":"Factors associated with interest in a long-acting HIV regimen: perspectives of people living with HIV and healthcare providers in four European countries","volume":"97","author":"Akinwunmi","year":"2021","journal-title":"Sex Transm Infect"},{"key":"2023071416150775400_ciad020-B9","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","article-title":"Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection","volume":"382","author":"Orkin","year":"2020","journal-title":"N Engl J Med"},{"key":"2023071416150775400_ciad020-B10","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/S0140-6736(20)32666-0","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2 M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study","volume":"396","author":"Overton","year":"2021","journal-title":"Lancet"},{"key":"2023071416150775400_ciad020-B11","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","article-title":"Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression","volume":"382","author":"Swindells","year":"2020","journal-title":"N Engl J Med"},{"key":"2023071416150775400_ciad020-B12","author":"European Medicines Agency"},{"key":"2023071416150775400_ciad020-B13","author":"ViiV Healthcare"},{"key":"2023071416150775400_ciad020-B14","author":"ViiV Healthcare"},{"key":"2023071416150775400_ciad020-B15"},{"key":"2023071416150775400_ciad020-B16","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/S2352-3018(20)30340-4","article-title":"Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study","volume":"8","author":"Orkin","year":"2021","journal-title":"Lancet HIV"},{"key":"2023071416150775400_ciad020-B17","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/QAD.0000000000003025","article-title":"Week 96 extension results of a phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment","volume":"36","author":"Swindells","year":"2022","journal-title":"AIDS (London, England)"},{"key":"2023071416150775400_ciad020-B18","doi-asserted-by":"crossref","first-page":"e679","DOI":"10.1016\/S2352-3018(21)00185-5","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2 M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study","volume":"8","author":"Jaeger","year":"2021","journal-title":"Lancet HIV"},{"key":"2023071416150775400_ciad020-B19","author":"ClinicalTrials.gov"},{"key":"2023071416150775400_ciad020-B20","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"key":"2023071416150775400_ciad020-B21"},{"key":"2023071416150775400_ciad020-B22","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1524-4733.2006.00121.x","article-title":"Validation of the revised 10-item HIV treatment satisfaction questionnaire status version and new change version","volume":"9","author":"Woodcock","year":"2006","journal-title":"Value Health"},{"key":"2023071416150775400_ciad020-B23","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1097\/QAD.0000000000002883","article-title":"Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis","volume":"35","author":"Cutrell","year":"2021","journal-title":"AIDS (London, England)"},{"key":"2023071416150775400_ciad020-B24","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/QAI.0000000000002449","article-title":"Brief report: durable suppression and low rate of virologic failure 3 years after switch to dolutegravir + rilpivirine 2-drug regimen: 148-week results from the SWORD-1 and SWORD-2 randomized clinical trials","volume":"85","author":"van Wyk","year":"2020","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"2023071416150775400_ciad020-B25","volume-title":"Poster presented at: 24th International AIDS Conference; 29 July\u20132 August 2022; Montreal, Canada, and virtual. Poster EPLBB05","author":"Jonsson-Oldenb\u00fcttel"},{"key":"2023071416150775400_ciad020-B26","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials","volume":"71","author":"Sax","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023071416150775400_ciad020-B27","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1007\/s10461-020-02929-8","article-title":"Patient-reported outcomes in ATLAS and FLAIR participants on long-acting regimens of cabotegravir and rilpivirine over 48 weeks","volume":"24","author":"Murray","year":"2020","journal-title":"AIDS Behav"},{"key":"2023071416150775400_ciad020-B28","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0140-6736(17)31917-7","article-title":"Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial","volume":"390","author":"Margolis","year":"2017","journal-title":"Lancet"},{"key":"2023071416150775400_ciad020-B29","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.3390\/pharmaceutics14081588","article-title":"Real-life therapeutic concentration monitoring of long-acting cabotegravir and rilpivirine: preliminary results of an ongoing prospective observational study in Switzerland","volume":"14","author":"Thoueille","year":"2022","journal-title":"Pharmaceutics"},{"key":"2023071416150775400_ciad020-B30","volume-title":"Poster presented at: HIV Glasgow; 5\u20138 October 2020; virtual. Poster P011","author":"Chounta"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciad020\/49121554\/ciad020.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/9\/1646\/50883545\/ciad020.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/9\/1646\/50883545\/ciad020.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T12:15:35Z","timestamp":1689336935000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/76\/9\/1646\/6993340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,20]]},"references-count":30,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,1,20]]},"published-print":{"date-parts":[[2023,5,3]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciad020","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5,1]]},"published":{"date-parts":[[2023,1,20]]}}}